In summary, despite the low proportion of PEPI scores of 0, tucidinostat plus exemestane may be well tolerated as neoadjuvant therapy in patients with early hormone receptor-positive, HER2-negative breast cancer. The gene discussed is ERBB2; the disease is breast cancer.